Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors

US6555686B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Pharma Company · US

Inventors

• Rodney Lawrence Parsons, Jr. · Wilmington, US
• Roberta L. Dorow · Portage, US
• Akin H. Davulcu · Wilmington, US
• Joseph M. Fortunak · Newark, US
• Gregory D. Harris · Wilmington, US
• Goss S. Kauffman · Ledyard, US
• William A. Nugent · Wilmington, US
• Lilian A. Radesca · Newark, US

Key dates

• Filing date: Jul 20, 2001
• Grant date: Apr 29, 2003
• Expiry date: Jul 20, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/80
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention relates generally to the asymmetric synthesis of quinazolin-2-ones that are useful as inhibitors of HIV reverse transcriptase. The synthesis is accomplished through the chiral ligand mediated addition of cyclopropylacetylide.